Boehringer Ingelheim and MiNA Therapeutics to develop novel treatment approaches for fibrotic liver diseases

Boehringer Ingelheim and MiNA Therapeutics ("MiNA"), a pioneer in RNA activation therapeutics, have signed a collaboration and licensing agreement focused on the development of novel compounds to treat fibrotic liver diseases such as NASH, based on MiNA's small activating RNA ("saRNA") therapeutics platform.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news